Recent Research on Gastrointestinal Carcinoma

Rovesti, Giulia; Marisi, Giorgia; Casadei-Gardini, Andrea

doi:10.3390/cancers13020333

Cited by 2 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A second pillar is formed by PD-L1-directed ICI therapy, showing positive data for the first-line and even perioperative setting, recently presented at ASCO 2021. Based on phase III trials such as CheckMate 649, Checkmate 577, Attraction 4 and KEYNOTE 590 showing convincing clinical improvement, the addition of ICIs (nivolumab or pembrolizumab) to chemotherapy or chemoradiation therapy (CRT) is now becoming the standard of care in the first-line setting of metastatic disease [3][4][5][6]. Another new treatment option is the addition of ICI therapy to Her2neu directed regimens in patients with ErbB2 overamplification.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Landscape of Biomarkers and Actionable Gene Alterations in Adenocarcinoma of GEJ and Stomach—A Real World Data Analysis

Hempel

Oliveira

Gäumann³

et al. 2021

Cancers

View full text Add to dashboard Cite

After several years of negative phase III trials in gastric and esophageal cancer, a significant breakthrough in the treatment of metastatic adenocarcinomas of the gastroesophageal junction (GEJ) and stomach (GC) is now becoming evident with the emerging of precision oncology and implementation of molecular targets in tumor treatment. In addition, new generation studies such as umbrella and basket trials are focused on these molecular targets, which makes an early molecular diagnosis based on IHC/ISH and NGS necessary. The required companion diagnostics of Her2neu overamplification or PD-L1 expression is based on immunohistochemistry (IHC) or additionally in situ hybridization (ISH) in case of an IHC Her2neu score of 2+. However, there are investigator-dependent differences in the assessment of Her2neu amplification and different PD-L1 scoring systems obtained by IHC/ISH. The use of high-throughput technologies such as next-generation sequencing (NGS) holds the potential to standardize the analysis and thus make them more comparable. In the presented study, real-world multigene sequencing data of 72 Caucasian patients diagnosed with metastatic adenocarcinomas of GEJ and stomach were analyzed. In the clinical companion diagnostics, we found ESCAT level I molecular targets in one-third of our patients, which directly determined the therapy. In addition, we found potential targets in 14/72 patients (19.4%) who potentially qualify for precision therapies in corresponding molecular studies. The study highlights the importance of comprehensive molecular profiling for precision treatment of GEJ/GC and indicates that a biomarker evaluation should be performed for all patients with metastatic adenocarcinomas before the initiation of first-line treatment and during second-line or subsequent treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

“…If detected, the fusion protein can serve as a therapeutic target for larotrectinib or entrictinib [5]. Other experimental therapeutic targets such as c-Met, ErbB3 and mTOR are under clinical evaluation [6,7]. The therapeutical landscape of GEJ and GC is becoming increasingly complex.…”

Section: Introductionmentioning

confidence: 99%